Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US11273210B2 · kind B2 · utility
0Cited by
4References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 29, 2018 |
| Grant date | Mar 15, 2022 |
| Priority date | — |
| Expiry date | Jun 29, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N5/0641
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is related to arginine deiminase encapsulated into erythrocytes for use in therapy. It is in particular related to the use thereof in treating arginase-1 deficiency. Also, it relates to novel pharmaceutical compositions comprising arginine deiminase from M. arginini encapsulated into erythrocytes and the use thereof in treating diseases that may benefit from arginine depletion, such as arginine dependent cancers, in particular arginine-auxotrophic cancers, and arginase-1 deficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.